A product in our regenerative medicine R & D pipeline to treat heart diseases for which radical therapies have not yet been established (e.g., ischemic heart disease and dilated cardiomyopathy). Our research partner is presently conducting a clinical research of the patch for dilated cardiomyopathy. The first patient to receive a patch was successfully treated and discharged from the hospital without requiring a ventricular assist device.
Product Concept and Characteristics
Appropriate therapies for severe heart diseases such as ischemic heart disease and dilated cardiomyopathy have long been sought, but radical therapies have proved elusive. The regenerated cardiac patch consists of a cell sheet cultured from patient-derived cells (e.g., myoblasts collected from the patient's thigh) using CellSeed's temperature-responsive cultureware. The patch is transplanted into the affected part of the heart, where the use of intact cell sheets allows transplanted cells to achieve a higher engraftment rate than by cell injection. The innovative technological advances embodied in regenerated cardiac patch therapy promise greater therapeutic benefits than could be obtained with conventional approaches.